Show simple item record

dc.contributor.authorAbdelmohsen, Usama Ramadan
dc.contributor.authorBalasubramanian, Srikkanth
dc.contributor.authorOelschlaeger, Tobias A
dc.contributor.authorGrkovic, Tanja
dc.contributor.authorNgoc, B Pham
dc.contributor.authorQuinn, Ronald J
dc.contributor.authorHentschel, Ute
dc.date.accessioned2017-08-14T03:56:06Z
dc.date.available2017-08-14T03:56:06Z
dc.date.issued2017
dc.identifier.issn1473-3099
dc.identifier.doi10.1016/S1473-3099(16)30323-1
dc.identifier.urihttp://hdl.handle.net/10072/343972
dc.description.abstractAntibiotics have revolutionised medicine in many aspects, and their discovery is considered a turning point in human history. However, the most serious consequence of the use of antibiotics is the concomitant development of resistance against them. The marine environment has proven to be a very rich source of diverse natural products with significant antibacterial, antifungal, antiviral, antiparasitic, antitumour, anti-inflammatory, antioxidant, and immunomodulatory activities. Many marine natural products (MNPs)—for example, neoechinulin B—have been found to be promising drug candidates to alleviate the mortality and morbidity rates caused by drug-resistant infections, and several MNP-based anti-infectives have already entered phase 1, 2, and 3 clinical trials, with six approved for usage by the US Food and Drug Administration and one by the EU. In this Review, we discuss the diversity of marine natural products that have shown in-vivo efficacy or in-vitro potential against drug-resistant infections of fungal, viral, and parasitic origin, and describe their mechanism of action. We highlight the drug-like physicochemical properties of the reported natural products that have bioactivity against drug-resistant pathogens in order to assess their drug potential. Difficulty in isolation and purification procedures, toxicity associated with the active compound, ecological impacts on natural environment, and insufficient investments by pharmaceutical companies are some of the clear reasons behind market failures and a poor pipeline of MNPs available to date. However, the diverse abundance of natural products in the marine environment could serve as a ray of light for the therapy of drug-resistant infections. Development of resistance-resistant antibiotics could be achieved via the coordinated networking of clinicians, microbiologists, natural product chemists, and pharmacologists together with pharmaceutical venture capitalist companies.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofpagefrome30
dc.relation.ispartofpagetoe41
dc.relation.ispartofissue2
dc.relation.ispartofjournalThe Lancet Infectious Diseases
dc.relation.ispartofvolume17
dc.subject.fieldofresearchMedical Microbiology not elsewhere classified
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchMedical Microbiology
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode110899
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1108
dc.subject.fieldofresearchcode1117
dc.titlePotential of marine natural products against drug-resistant fungal, viral, and parasitic infections
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.hasfulltextNo Full Text
gro.griffith.authorQuinn, Ronald J.
gro.griffith.authorPham, Ngoc B.
gro.griffith.authorGrkovic, Tanja


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record